Table 2 Summary of clinical features of published reports according to the types of concurrence carcinomas*
Primary neoplasm (n) | Age(range/ median) | Gender (M/F) | The top three symptoms (%)*** | The top three locations (%) | The top three treatments (%) | Recurrence or progress rate % (n) |
|---|---|---|---|---|---|---|
VA (34) | (23–88 /61.5) | (19/14)** | 1. Hematuria (32.4) | 1. Bladder dome (26.5) | 1. TUR (32.4) | 2.9%: (1/34 cases) |
2. Irritative symptom (17.6) | 2. Bladder (20.6) | 2. Unknown (20.6) | ||||
3. Unknown (17.6) | 3. Posterior wall (8.8) | 3. None (17.6) | ||||
VA + AD (24) | (31–94 /65.5) | (14/10) | 1. Hematuria (33.3) | 1. Bladder (37.5) | 1. TUR (29.2) | 20.8%: (5/24 cases) |
2. Irritative symptom (29.2) | 2. Urethra (33.3) | 2. Total cystectomy (20.8) | ||||
3. Abdminal pain (8.3) | 3. Bladder dome (16.7) | 3. Partial cystectomy (16.7) | ||||
VA + AD + UC (2) | (76–92 /84) | (2/0) | 1. Unknown (100) | 1. Bladder (100) | 1. TUR (100) | 0%: (0/2 cases) |
VA + UC (2) | (66–85 /75.5) | (1/1) | 1. Hematuria (50.0) | 1. Bladder (33.3) | 1. Partial cystectomy (50.0) | 100%: (2/2 cases) |
1. Urachus (33.3) | ||||||
1. TUR (50.0) | ||||||
1. Lateral wall (33.3) |